AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27456983 — intervention group
Group type: EXPERIMENTAL
Intervention: Protease inhibitor monotherapy
Number of subjects: 290
Study 27456983 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche TaqMan‐2 assay
Number of subjects: 290
Study 24708623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored implementation strategy for enhancing adherence to COPD management guidelines (including brief anti-smoking advice, dyspnea assessment, care checklist utilization, and demonstration of correct inhaler use)
Number of subjects: 1440
Study 24708623 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by control practices
Number of subjects: 1440
Study 22310542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir plus azithothymidine/3TC
Number of subjects: 43
Study 22310542 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz plus azithothymidine/3TC
Number of subjects: 43
Study 22310542 — intervention group
Group type: EXPERIMENTAL
Intervention: Geno2pheno([clinical]) FPR analysis
Number of subjects: 43
Study 22310542 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmitted drug resistance mutations
Number of subjects: 43
Study 20178875 — intervention group
Group type: EXPERIMENTAL
Intervention: Western medicine (WM) - Terazosin Hydrochloride Hytrin (THH)
Number of subjects: 61
Study 20178875 — intervention group
Group type: COMPARATOR
Intervention: Traditional Chinese medicine (TCM) - herbal Saxifrage tablet (HST)
Number of subjects: 61
Study 20178875 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (WM and TCM)
Number of subjects: 61
Study 16636816 — intervention group
Group type: EXPERIMENTAL
Intervention: Back care + physical activity promotion program
Number of subjects: 555
Study 16636816 — intervention group
Group type: EXPERIMENTAL
Intervention: Back care program
Number of subjects: 555
Study 16636816 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 555
Study 16255016 — intervention group
Group type: EXPERIMENTAL
Intervention: IA yttrium‐90 plus glucocorticoids (GCs)
Number of subjects: 97
Study 16255016 — intervention group
Group type: COMPARATOR
Intervention: IA placebo yttrium plus glucocorticoids (GCs)
Number of subjects: 97
Study 12131599 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 390
Study 12131599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study 15251662 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (1.5 to 2.0 mg/kg of body weight daily)
Number of subjects: 62
Study 15251662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 7734104 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ICR
Number of subjects: 384
Study 7734104 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ICR
Number of subjects: 384
Study 7734104 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg ICR
Number of subjects: 384
Study 7734104 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ICR
Number of subjects: 384
Study 7734104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 2390689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 5 FU
Number of subjects: 4
Study 2390689 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal administration of 5 FU
Number of subjects: 4
Study 2390689 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of fluoro‐beta‐alanine (FBAL)
Number of subjects: 4
Study 396658 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 20
Study 396658 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31987536 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus nanoparticle gel applied by phonophoresis (PP)
Number of subjects: 40
Study 31987536 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound therapy (UT)
Number of subjects: 40
Study 31469816 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab plus ipilimumab (first-line treatment)
Number of subjects: 847
Study 31469816 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (second-line treatment)
Number of subjects: 847
Study 28492860 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept, 2.0 mg
Number of subjects: 362
Study 28492860 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab, 1.25 mg
Number of subjects: 362
Study 28492860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 362
Study 28492860 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF treatment prior to study participation
Number of subjects: 362
Study 25931733 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper thoracic manipulation after cervical stability training
Number of subjects: 30
Study 25931733 — intervention group
Group type: COMPARATOR
Intervention: Cervical stability training alone
Number of subjects: 30
Study 24332416 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents
Number of subjects: 607
Study 24332416 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents
Number of subjects: 607
Study 24332416 — intervention group
Group type: EXPERIMENTAL
Intervention: True bifurcation lesion (TBL)
Number of subjects: 607
Study 24332416 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple stents
Number of subjects: 607
Study 24332416 — intervention group
Group type: EXPERIMENTAL
Intervention: Culotte stenting
Number of subjects: 607
Study 24332416 — intervention group
Group type: EXPERIMENTAL
Intervention: SYNTAX scores
Number of subjects: 607
Study 22717102 — intervention group
Group type: EXPERIMENTAL
Intervention: OPRM1 genotype (G allele presence) among non-Hispanic whites
Number of subjects: 247
Study 22717102 — intervention group
Group type: EXPERIMENTAL
Intervention: OPRM1 genotype (G allele presence) among Hispanics
Number of subjects: 247
Study 22717102 — intervention group
Group type: EXPERIMENTAL
Intervention: OPRM1 genotype (G allele presence) among African Americans
Number of subjects: 247
Study 19244157 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity
Number of subjects: 102
Study 19244157 — intervention group
Group type: COMPARATOR
Intervention: Health education (Control)
Number of subjects: 102
Study 17132678 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified milk
Number of subjects: 633
Study 17132678 — intervention group
Group type: COMPARATOR
Intervention: Control milk
Number of subjects: 633
Study 15488105 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm reduction approaches
Number of subjects: 0
Study 15488105 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacious interventions
Number of subjects: 0
Study 15488105 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized treatment efficacy trials
Number of subjects: 0
Study 15488105 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual difference variables
Number of subjects: 0
Study 15488105 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdisciplinary research
Number of subjects: 0
Study 11241122 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants
Number of subjects: 1326
Study 9763798 — intervention group
Group type: EXPERIMENTAL
Intervention: Running during the fourth stage of the Bruce treadmill protocol
Number of subjects: 27
Study 9763798 — intervention group
Group type: COMPARATOR
Intervention: Walking during the fourth stage of the Bruce treadmill protocol
Number of subjects: 27
Study 7812072 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg/day Calcium supplements (two different forms)
Number of subjects: 156
Study 7812072 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplements (in fractured patients)
Number of subjects: 156
Study 7812072 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 156
Study 2338120 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac hydroxyethylpyrrolidine (DIEP) 2 X 50 mg
Number of subjects: 0
Study 2338120 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium 2 X 50 mg
Number of subjects: 0
Study 2338120 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AUC values
Number of subjects: 0
Study 879220 — intervention group
Group type: EXPERIMENTAL
Intervention: Deceleration Delay Index (DDI)
Number of subjects: 106
Study 31126971 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention 1
Number of subjects: 360
Study 31126971 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based intervention 2
Number of subjects: 360
Study 31126971 — intervention group
Group type: COMPARATOR
Intervention: Education-only control group
Number of subjects: 360
Study 31126971 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based interventions
Number of subjects: 360
Study 28975429 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-oral cooling device
Number of subjects: 20
Study 28975429 — intervention group
Group type: COMPARATOR
Intervention: Ice chips
Number of subjects: 20
Study 24801607 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive activity (CA) strategy training
Number of subjects: 160
Study 24801607 — intervention group
Group type: COMPARATOR
Intervention: Control nonspecific educational program
Number of subjects: 160
Study 23639862 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowman Birk Inhibitor Concentrate (BBIC)
Number of subjects: 132
Study 23639862 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 20693809 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy + infliximab
Number of subjects: 33
Study 20693809 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 33
Study 19805692 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral satraplatin (80 mg/m² on days 1 to 5 of a 35-day cycle) and prednisone (5 mg twice daily)
Number of subjects: 950
Study 19805692 — intervention group
Group type: COMPARATOR
Intervention: Placebo and prednisone (5 mg twice daily)
Number of subjects: 950
Study 16715948 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-citrate
Number of subjects: 35
Study 16715948 — intervention group
Group type: EXPERIMENTAL
Intervention: 90Y-silicate
Number of subjects: 35
Study 16715948 — intervention group
Group type: EXPERIMENTAL
Intervention: 186Re-sulfide
Number of subjects: 35
Study 16715948 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 35
Study 15875093 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (5 mg/daily)
Number of subjects: 1802
Study 15875093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1802
Study 12533364 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic sliding loop suture technique
Number of subjects: 37
Study 12533364 — intervention group
Group type: COMPARATOR
Intervention: Traditional suture technique
Number of subjects: 37
Study 10192656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogen replacement therapy (2 mg of 17-beta-oestradiol orally for 3 months)
Number of subjects: 25
Study 10192656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7766744 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent ranitidine (300 mg)
Number of subjects: 12
Study 7766744 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular ranitidine (300 mg)
Number of subjects: 12
Study 7766744 — intervention group
Group type: EXPERIMENTAL
Intervention: Effervescent cimetidine (800 mg)
Number of subjects: 12
Study 7766744 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cimetidine (800 mg)
Number of subjects: 12
Study 2148702 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak flow self management plan
Number of subjects: 115
Study 2148702 — intervention group
Group type: COMPARATOR
Intervention: Symptoms only self management plan
Number of subjects: 115
Study 6108264 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine
Number of subjects: 110
Study 6108264 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 12480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of [3H]L-arginine (300 nCi/min)
Number of subjects: 7
Study 12480822 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial samples from patients with CHF
Number of subjects: 7
Study 31342375 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid
Number of subjects: 201
Study 31342375 — intervention group
Group type: COMPARATOR
Intervention: High-quality websites
Number of subjects: 201
Study 29882070 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI with cetuximab
Number of subjects: 592
Study 29882070 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI with bevacizumab
Number of subjects: 592
Study 29882070 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean attenuation ≥61.62 HU
Number of subjects: 592
Study 26830643 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic epidural catheter threading distance of 7 cm
Number of subjects: 120
Study 26830643 — intervention group
Group type: COMPARATOR
Intervention: Combined thoracic epidural catheter threading distances of 3 cm and 5 cm
Number of subjects: 120
Study 26830643 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (3CM, 5CM, 7CM)
Number of subjects: 120
Study 23773323 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant delusional themes at baseline
Number of subjects: 411
Study 23773323 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments at years 1, 2, and 5
Number of subjects: 411
Study 22702369 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified pulmonary vein isolation (PVI)
Number of subjects: 126
Study 22702369 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary vein isolation (PVI)
Number of subjects: 126
Study 20478070 — intervention group
Group type: EXPERIMENTAL
Intervention: Newhints intervention (routine home visits providing essential newborn care interventions)
Number of subjects: 15000
Study 20478070 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 15000
Study 17566093 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 125 mg
Number of subjects: 131
Study 17566093 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 250 mg
Number of subjects: 131
Study 17566093 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide 375 mg
Number of subjects: 131
Study 17566093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 16139123 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan with aspirin (n = 1,004)
Number of subjects: 9193
Study 16139123 — intervention group
Group type: COMPARATOR
Intervention: Atenolol with aspirin (n = 966)
Number of subjects: 9193
Study 16139123 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan with aspirin
Number of subjects: 9193
Study 16139123 — intervention group
Group type: COMPARATOR
Intervention: Atenolol with aspirin
Number of subjects: 9193
Study 12177584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 150
Study 12177584 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 150
Study 10551346 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (C)
Number of subjects: 15
Study 10551346 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (P)
Number of subjects: 15
Study 7844608 — intervention group
Group type: COMPARATOR
Intervention: HFX RT with 1.2 Gy twice daily to a total dose of 64.8 Gy (group I)
Number of subjects: 169
Study 7844608 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with CHT (100 mg of carboplatin on days 1 and 2 and 100 mg of etoposide on days 1 to 3 of each week during RT course) (group II)
Number of subjects: 169
Study 7844608 — intervention group
Group type: EXPERIMENTAL
Intervention: HFX RT with CHT (200 mg of carboplatin on days 1 and 2 and 100 mg of etoposide on days 1 to 5 of the first, third, and fifth weeks of RT course) (group III)
Number of subjects: 169
Study 2189903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 6 mg tid
Number of subjects: 84
Study 2189903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 8 mg tid
Number of subjects: 84
Study 2189903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilvadipine 10 mg tid
Number of subjects: 84
Study 2189903 — intervention group
Group type: COMPARATOR
Intervention: Nilvadipine
Number of subjects: 84
Study 442709 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 12
Study 442709 — intervention group
Group type: COMPARATOR
Intervention: Caffeine-free coffee
Number of subjects: 12
Study 31196026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined telephone and SMS intervention
Number of subjects: 750
Study 31196026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 750
Study 27529732 — intervention group
Group type: EXPERIMENTAL
Intervention: One-jaw surgery
Number of subjects: 30
Study 27529732 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-jaw surgery
Number of subjects: 30
Study 27529732 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic camouflage treatment (OCT)
Number of subjects: 30
Study 25546447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip flexor stretch (HFS)
Number of subjects: 15
Study 25546447 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 15
Study 25546447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip extensor stretch (HES)
Number of subjects: 15
Study 24113783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pazopanib 15 mg daily (patients with AMD)
Number of subjects: 15
Study 24113783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pazopanib up to 30 mg daily (healthy participants)
Number of subjects: 15
Study 24113783 — intervention group
Group type: COMPARATOR
Intervention: Rescue therapy (for patients with AMD)
Number of subjects: 15
Study 24113783 — intervention group
Group type: EXPERIMENTAL
Intervention: CFH Y402H T allele ('low risk' for AMD, n = 6)
Number of subjects: 15
Study 21734019 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery
Number of subjects: 0
Study 18653310 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavior therapy (CBT)
Number of subjects: 0
Study 18653310 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive behavior therapy (CBT)
Number of subjects: 0
Study 18653310 — intervention group
Group type: COMPARATOR
Intervention: Educational/supportive psychotherapy (control)
Number of subjects: 0
Study 17101568 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoCinch plication technique
Number of subjects: 46
Study 17101568 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (Control)
Number of subjects: 46
Study 17016954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified dietary supplement (25 g per school day for children; two 25-g sachets per day for pregnant women)
Number of subjects: 0
Study 17016954 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified dietary supplement
Number of subjects: 0
Study 17016954 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified supplement
Number of subjects: 0
Study 11106884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with more hospitalizations and emergency room visits in the prior 6 months
Number of subjects: 1378
Study 11106884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with higher blood urea nitrogen
Number of subjects: 1378
Study 11106884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower mental health function
Number of subjects: 1378
Study 11106884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a diagnosis of COPD
Number of subjects: 1378
Study 11106884 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with increased satisfaction with access to emergency care
Number of subjects: 1378
Study 11106884 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population of 1378 patients
Number of subjects: 1378
Study 8723804 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal instillation of large doses of bovine and porcine lung-derived surfactant preparations
Number of subjects: 0
Study 8723804 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1677276 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic feedback training with contingent tone based on oral-lingual movements above a yoked threshold.
Number of subjects: 20
Study 1677276 — intervention group
Group type: COMPARATOR
Intervention: Noncontingent feedback tones generated randomly.
Number of subjects: 20
Study 6129933 — intervention group
Group type: EXPERIMENTAL
Intervention: Almitrine (1 mg/kg intravenously)
Number of subjects: 7
Study 6129933 — intervention group
Group type: COMPARATOR
Intervention: Solvent (placebo)
Number of subjects: 7
Study 31471504 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI ≥30 kg/m2
Number of subjects: 120607
Study 31471504 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure ≥160/100 mm Hg
Number of subjects: 120607
Study 29137107 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 92
Study 29137107 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 92
Study 25968303 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalised trauma tertiary survey (TTS) procedure
Number of subjects: 6380
Study 25968303 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 6380
Study 22552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based therapy (DP) following ketoconazole (KC)
Number of subjects: 220
Study 22552048 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel-based therapy (DP) in KC-naive patients
Number of subjects: 220
Study 21718804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (650 mg daily, containing 250-280 mg DHA and at least 60 mg EPA)
Number of subjects: 0
Study 21718804 — intervention group
Group type: COMPARATOR
Intervention: Olive oil supplementation (placebo)
Number of subjects: 0
Study 21718804 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (650 mg daily)
Number of subjects: 0
Study 19918596 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia frameworks cemented with glass-ionomer cement
Number of subjects: 30
Study 19918596 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (contralateral analogous teeth)
Number of subjects: 30